[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":664},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,76,0,25,[9,40,68,98,129,157,180,209,235,260,285,305,329,358,388,409,435,457,483,509,535,557,583,617,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100645007","phase-3-retlirafusp-alfa-injection-plus-chemotherapy-versus-investigators-choice-of-anti-pd-1-antibody-plus-chemotherapy-as-first-line-treatment-for-advanced-gastric-cancer-with-liver-metastases-100645007",false,"NCT07677293","Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases","Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy for Previously Untreated, Advanced Gastric or Gastroesophageal Junction Cancer With Liver Metastases: a Randomized, Controlled, Multicenter Phase III Clinical Study","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years; 2. Patients with recurrent or previously untreated advanced gastric or gastroesophageal junction cancer with liver metastases, histopathologically confirmed as adenocarcinoma.\n\n  3\\. No prior systemic therapy (including anti-HER2 therapy) for advanced or metastatic GC\u002FGEJC. Patients who have received prior adjuvant or neoadjuvant therapy are eligible provided that the time from completion of last therapy to first recurrence or disease progression is \\> 6 months.\n\n  4\\. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 5. At least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\n  6\\. Adequate organ and bone marrow function. 7. Female subjects of non-childbearing potential are defined as those who are postmenopausal, or have undergone documented hysterectomy and\u002For bilateral oophorectomy. Male subjects and female subjects of childbearing potential must agree to use at least one medically approved contraceptive method during the study and for 120 days after the last dose of study treatment. A serum pregnancy test must be negative within 3 days prior to the start of study treatment, and subjects must not be breastfeeding.\n\n  8\\. Voluntarily signed informed consent, and willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* 1\\. Known gastric cancer of squamous cell carcinoma, undifferentiated carcinoma, or other histological types, or adenocarcinoma mixed with other histological types.\n\n  2\\. Untreated or inadequately treated central nervous system (CNS) metastases, or uncontrolled or symptomatic active CNS metastases.\n\n  3\\. Diagnosis of any other malignancy within 5 years prior to study entry, except for: skin basal cell carcinoma or squamous cell carcinoma that has been locally treated and documented as cured, superficial bladder cancer, cervical carcinoma in situ, breast ductal carcinoma in situ, papillary thyroid carcinoma, and other early-stage tumors with low risk of recurrence that have undergone curative treatment as judged by the investigator.\n\n  4\\. Presence of any active, known, or suspected autoimmune disease. 5. Prior treatment with TGF-β inhibitors, anti-PD-1\u002FPD-L1 antibodies, anti-PD-L2 antibodies, anti-CD137 antibodies, CTLA-4 antibodies, or other drugs\u002Fantibodies targeting T-cell costimulatory or checkpoint pathways.\n\n  6\\. Severe, non-healing, or dehiscent wound, or active ulcer, or untreated fracture.\n\n  7\\. Any other serious physical or mental illness, or laboratory abnormalities that may increase the risk of study participation, interfere with study results, or render the subject unsuitable for the study judged by the investigator.","ALL","18 Years",{"count":20,"type":21},332,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) with liver metastases",[27],"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":21},"2026-06-26",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Peking University","OTHER",{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100557709","phase-1-evm16-injection-as-a-single-and-combination-with-tislelizumab-in-solid-tumors-100557709","NCT06541639","EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors","A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection as a Single and Combination With Tislelizumab in Subjects With Advanced or Recurrent Solid Tumors","Key Inclusion Criteria:\n\n* Recurrent or metastatic solid tumors that have been histologically or cytologically pathologically confirmed and are not amenable to radical treatment with surgery or local therapy.\n* Patients with advanced or recurrent solid tumors who have failed prior standard therapy.\n* Expected survival period \\>6 weeks at the time of informed consent.\n* Adequate organ function\n* Eastern Cooperative Oncology Group (ECOG) Physical Status Score 0 to 1.\n* Is willing to provide archival or fresh tumor tissue samples for EVM16 production.\n* Has adequate treatment washout period prior to first study dose.\n* Has at least one measurable lesion as assessed by the investigator according to RECIST version 1.1 criteria before enrollment.\n\nKey Exclusion Criteria:\n\n* Primary central nervous system (CNS) malignancies that are symptomatic, untreated, or in need of curative treatment, or subjects with CNS metastases.\n* Uncontrolled co-morbidities.\n* Cerebrovascular event (stroke, transient ischemic attack, etc.) within 4 months prior to the signing of inform consent form.\n* In screening period male QTcF interval \\>450 ms; Female QTcF interval \\>470 ms (calculated by the Fridericia formula).\n* Left ventricular ejection fraction (LVEF) \\\u003C 50% during the screening period.\n* Diagnosis of immunodeficiency, or history or syndrome of active as well as former autoimmune disease with risk of relapse, or a disease requiring systemic steroid hormone or immunosuppressive drug therapy.\n* Subjects with a history of positive human immunodeficiency virus (HIV) test or acquired immunodeficiency syndrome (AIDS).\n* Co-infection HBV and HCV.\n* Presence of any active infection requiring systemic therapy.\n* Patients who are still on any other investigational medications treatment at the time of screening.\n* Previous treatment with cell therapy, tumor vaccines, cytokines, or growth factors for cancer control.\n* Patients with prior intolerance to tislelizumab resulting in permanent termination of tislelizumab.\n* History or presence of significant lung disease.",{"count":48,"type":21},78,[50],"PHASE1","The goal of this clinical trial is to learn the side effects, safety and effect of a tumor vaccine (EVM16) alone or in combined with an anti-PD-1 antibody (tislelizumab) . This clinical trial will include solid tumor patients who failed standard treatment.\n\nThe main questions to answer are:\n\nSafety of EVM16. Suitable dose of EVM16. Effects of EVM16 combined with tislelizumab.",[53],"Advanced or Recurrent Solid Tumors",[55,56,57],"solid tumor","tumor vaccine","immune checkpoint inhibitor","RECRUITING","2026-06-17",{"date":61,"type":32},"2026-06-22",{"date":63,"type":32},"2025-03-04",{"date":65,"type":21},"2028-12",{"name":38,"class":39},2,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100642033","phase-4-botulinum-toxin-type-a-injection-sites-for-oral-commissure-ptosis-100642033","NCT07646886","Botulinum Toxin Type A Injection Sites for Oral Commissure Ptosis","Injection Site-Based Multicenter Randomized Controlled Trial: Efficacy and Safety of Focal Botulinum Toxin Type A Injection for Oral Commissure Ptosis","Inclusion Criteria:\n\n* Aged 18 to 60 years, any gender\n* Meet the diagnostic criteria for oral commissure ptosis: bilateral oral commissure ptosis angle (angle between the oral commissure point and the horizontal line of the ipsilateral vermilion border) \\> 1° at rest\n* Have clear aesthetic demand for oral commissure ptosis improvement and can complete full-cycle follow-up\n* No redness, swelling, ulcer, scar, deformity or active infection in the perioral and mental regions\n* Have not participated in other interventional clinical trials within 3 months before enrollment\n\nExclusion Criteria:\n\n* Hypersensitivity to botulinum toxin type A, lidocaine or excipients of injection preparations; or contraindications to botulinum toxin injection (myasthenia gravis, Lambert-Eaton syndrome, motor neuron disease, severe liver and kidney dysfunction, coagulation disorders, uncontrolled autoimmune diseases, malignant tumors)\n* History of mid-lower facial botulinum toxin type A injection, soft tissue filling, laser\u002Fradiofrequency rejuvenation, perioral surgery or orthognathic treatment within 6 months before enrollment\n* Planned perioral treatment within 6 months after enrollment that may affect efficacy evaluation\n* Pregnant or lactating women, or those planning to become pregnant within 6 months\n* Acquired oral commissure ptosis caused by facial nerve palsy\u002Fsequelae, perioral scar traction, severe jaw deformity or severe alveolar bone resorption\n* Severe facial asymmetry (difference in bilateral oral commissure ptosis angle \\> 2°)\n* History of botulinum toxin allergy or severe adverse reactions after previous botulinum toxin injection\n* Currently using aminoglycoside antibiotics, quinine, calcium channel blockers, anticoagulants or other drugs that may affect botulinum toxin efficacy or increase bleeding risk and cannot discontinue\n* History of mental illness, drug\u002Falcohol abuse, or poor compliance unable to complete follow-up\n* Other conditions deemed unsuitable for enrollment by the investigator","60 Years",{"count":77,"type":21},266,[79],"PHASE4","This multicenter, prospective, randomized parallel-controlled, assessor-blinded clinical trial aims to address the core clinical pain point of lack of high-level evidence and non-standardized operation in injection site selection for BTX-A treatment of oral commissure ptosis. A total of 266 eligible subjects will be randomly assigned in a 1:1 ratio to receive either upper DAO or lower DAO BTX-A injection. The study will compare the clinical efficacy, time-effect characteristics and safety profiles of the two regimens, and conduct stratified analysis of treatment response in different patient subtypes. The results will determine the optimal injection site for Chinese population, establish standardized operation specifications, fill the international evidence gap, and provide level I evidence for clinical practice.",[82,83,84],"Facial Aging","Melomental Folds","Oral Commissure Ptosis",[86,84,83,87,88,89],"Botulinum Toxin Type A","Depressor Anguli Oris Muscle","Randomized Controlled Trial","Injection Site","2026-06-11",{"date":92,"type":32},"2026-06-15",{"date":94,"type":21},"2026-07-01",{"date":96,"type":21},"2027-12-01",{"name":38,"class":39},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100539629","3d-facial-scanning-for-evaluating-autologous-fat-grafting-in-craniofacial-deformities-100539629","NCT06306326","3D Facial Scanning for Evaluating Autologous Fat Grafting in Craniofacial Deformities","Application of Three-dimensional Facial Scanning Images in Evaluating the Therapeutic Efficacy of Autologous Fat Grafting in the Treatment of Craniofacial Deformities","Inclusion Criteria:\n\n* Facial soft tissue volume deficiency deformity caused by congenital\u002Facquired factors, meeting the indications for autologous fat grafting surgery.\n* Good physical health, without severe systemic diseases or infectious diseases.\n* Not pregnant and without plans for pregnancy.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Contraindications to general anesthesia.\n* Patient refusal to participate in this study.\n* Significant contour changes in non-filled facial areas during follow-up period leading to inability to register data.",true,"3 Years","80 Years",{"count":109,"type":21},100,[111],"NA","Treatment of craniofacial deformities is a significant topic in oral and maxillofacial surgery, and autologous fat grafting has become one of the main methods for treating facial concave deformities. However, the instability of its treatment effect has always been a bottleneck in this field, mainly due to the uncertain absorption rate of transplanted fat. This project aims to use advanced the 3dMD face system (3dMD) (3dMD Inc, Atlanta, Ga) technology to precisely measure the facial volume changes before and after autologous fat grafting to address this issue. By performing autologous fat grafting surgery on 100 patients with craniofacial deformities that meet the research criteria, 3dMD technology will be used for facial three-dimensional scanning preoperatively, immediately postoperatively, and at six months postoperatively to obtain facial volume data. Then, through precise data analysis, we will calculate the fat absorption rate and study the effects of individual factors on treatment outcomes through correlation regression analysis.",[114,115,116],"Adipocytes","Autografts","Imaging, Three-Dimensional \u002F Methods",[118,119],"Autologous Fat Grafting","3dMD","2026-06-05",{"date":122,"type":32},"2026-06-09",{"date":124,"type":32},"2024-04-27",{"date":126,"type":21},"2029-04-15",{"name":38,"class":39},1,{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":128},"100638026","salt-sensitivity-evaluation-via-n-of-1-trials-sense-salt-100638026","NCT07614724","Salt Sensitivity Evaluation Via N-of-1 Trials (SENSE-Salt)","Determining the Presence of Salt Sensitivity in Individuals With Elevated Blood Pressure Through Dietary Salt Interventions: A Series of N-of-1 Trials","SENSE-Salt","Phase 1: Salt Sensitivity Screening\n\nInclusion:\n\n1. Signed informed consent for the salt sensitivity test.\n2. Systolic blood pressure between 110-159 mmHg and diastolic blood pressure between 70-99 mmHg.\n3. Not taking any antihypertensive medication, or have had a stable antihypertensive regimen for the past three months and agree not to adjust their medication during the study period.\n4. Able to comply with consuming the study-provided diet throughout the study period.\n\nExclusion:\n\n1. Special dietary requirements, such as allergies to common foods (e.g., eggs, seafood, peanuts), or conditions like asthma, irritable bowel syndrome, lactose intolerance, chronic kidney disease stage 4 or higher, history of gastrointestinal surgery, or special dietary needs due to other illnesses, surgery, or weight loss.\n2. Diagnosed with chronic diseases: any malignancy with a life expectancy of less than one year; chronic heart failure, severe depression or other mental disorders, long-term bedridden status, or mobility limitations.\n3. Experienced acute myocardial infarction or stroke within the past 6 months.\n4. Acute illnesses such as upper respiratory tract infection, fever, or severe diarrhea that have not yet resolved.\n5. Alcohol abuse.\n6. Pregnant or breastfeeding women, or women planning to become pregnant.\n7. Individuals who are deaf, mute, or have cognitive impairments that hinder communication.\n\nPhase 2: N-of-1 Trial\n\nInclusion:\n\n1. Classified as salt-sensitive or salt-resistant through the Phase 1 screening:\n2. Salt-Sensitive (SS) Group: Participants with a change in mean arterial pressure (ΔMAP) ≥ 5 mmHg and in the upper 1\u002F6 of the distribution of ΔMAP from the salt sensitivity test.\n3. Salt-Resistant (SR) Group: Participants with a change in mean arterial pressure (ΔMAP) \\\u003C 5 mmHg and in the lower 1\u002F6 of the distribution of ΔMAP from the salt sensitivity test.\n4. Signed informed consent for the n-of-1 trial.\n\nExclusion:\n\n1. Failed to complete the salt sensitivity test as required, or consumed less than 80% of the study-provided meals during the salt sensitivity test (i.e., fewer than 34 meals over 14 days).\n2. Experienced adverse events during the salt sensitivity test that, in the investigator's judgment, make it inappropriate to continue in the study.","20 Years","65 Years",{"count":140,"type":21},72,[111],"Study Title: Determining the Presence of Salt Sensitivity in Individuals With Elevated Blood Pressure Through Dietary Salt Interventions: A Series of N-of-1 Trials\n\nObjective: To evaluate whether there are differences in blood pressure responses to dietary sodium intake between salt-sensitive and salt-resistant individuals, as identified through a salt sensitivity test. The study will use repeated dietary interventions with varying sodium content (high-sodium, low-sodium) to assess blood pressure responses in each individual, aiming to determine whether salt sensitivity is a present characteristic.\n\nStudy Design: This study will utilize an N-of-1 randomized controlled trial design. It consists of two phases:\n\nSalt Sensitivity Screening: A 2-week chronic salt-loading test will be used to identify salt-sensitive and salt-resistant individuals.\n\nN-of-1 Trial: The identified salt-sensitive and salt-resistant individuals will undergo a 6-week N-of-1 trial, consisting of three cycles, with each cycle including one week of low-sodium diet and one week of high-sodium diet. This design aims to assess individual blood pressure responses to changes in sodium intake.\n\nSample Size: A total of 72 participants will be recruited for the salt sensitivity screening, with an expected 24 participants proceeding to the N-of-1 trial.\n\nStudy Population: Healthy individuals aged 20-65 years, not on antihypertensive medication or with a stable regimen for at least 3 months, with systolic blood pressure between 110-159 mmHg and diastolic blood pressure between 70-99 mmHg, who are able to eat at the research center.\n\nPrimary Outcome: Reproducibility of salt sensitivity response classification. Secondary Outcomes: Changes in mean arterial pressure, systolic and diastolic blood pressure; exploratory outcomes such as sleep, mood, gut microbiome, metabolomics; safety outcomes including hypotension and hyponatremia.",[144,145],"Salt-Sensitivity of Blood Pressure","Hypertension",[147,148],"blood pressure","salt-sensitivity","2026-05-22",{"date":151,"type":32},"2026-05-29",{"date":153,"type":21},"2026-06-01",{"date":155,"type":21},"2026-11-30",{"name":38,"class":39},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":106,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":128},"100633877","fms-crossfit-training-program-fctp-to-improve-school-readiness-in-preschool-children-with-autism-spectrum-disorder-100633877","NCT07532395","FMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder","A Randomized Controlled Trial of the FMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder","Inclusion Criteria:\n\n1. age 3-6 years;\n2. confirmed ASD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria or the Autism Diagnostic Observation Schedule-Second Edition (ADOS-2);\n3. written informed consent from parent\u002Fcaregiver.\n\nExclusion Criteria:\n\n1. participation in structured exercise programs within the preceding 6 months;\n2. comorbid severe neurological disorders (e.g., epilepsy, phenylketonuria, fragile X syndrome, tuberous sclerosis) or major psychiatric conditions (e.g., schizophrenia, bipolar disorder);\n3. visual, auditory or intellectual impairments that would interfere with participation;\n4. history of significant head trauma or brain injury;\n5. medical contraindications to physical activity ;\n6. other factors deemed unsuitable for program participation by the research team.","6 Years",{"count":166,"type":21},184,[111],"Autism spectrum disorder (ASD) is an increasing public health concern, with preschool children often exhibiting persistent deficits in school readiness. However, targeted and developmentally comprehensive interventions remain limited. This randomized controlled trial will evaluate a 12-week Fundamental Movement Skills-CrossFit Training Program (FCTP) in 184 children with ASD aged 3-6 years, compared with a Treatment As Usual (TAU) control group. The program integrates progressive FMS training with CrossFit-style circuit training to improve motor competence, social interaction, and self-regulation. Primary outcomes focus on school readiness assessed by the Strengths and Difficulties Questionnaire (SDQ), while secondary outcomes include motor development, executive function, social responsiveness, and biomarkers. Assessments will be conducted at baseline, mid-intervention (8 weeks), post-intervention (12 weeks), and follow-up (20 weeks).",[170],"Autism Spectrum Disorder",[170,172],"CrossFit",{"date":174,"type":32},"2026-05-27",{"date":176,"type":32},"2025-11-22",{"date":178,"type":21},"2027-04-24",{"name":38,"class":39},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":191,"conditions":192,"keywords":197,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":128},"100560701","phase-2-immune-checkpoint-inhibitors-for-organ-preservation-in-non-metastatic-dmmrmsi-h-gastric-or-colon-cancers-100560701","NCT06580574","Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR\u002FMSI-H Gastric or Colon Cancers","PD-1\u002FPD-L1 Antibody With Selective Combination of Sintilimab, IBI310 and Lenvatinib Used for Organ Preservation in Non-metastatic Gastric or Colon Cancers With Mismatch Repair Deficiency or High Microsatellite Instability","Inclusion Criteria:\n\n* Subjects are able to comprehend the informed consent form, and voluntarily sign the informed consent form.\n* Subjects are ≥18 years old on the day of signing the informed consent form, with no gender restrictions.\n* Histologically confirmed gastric cancer or colon cancer, without distant metastasis based on CR or MR.\n* ECOG performance status of 0-2.\n* dMMR confirmed by immunohistochemistry or MSI-H confirmed by PCR and NGS. If MSI status and MMR status were not consistent, whether to enroll this patient should be determine by investigators. Patients with MMR heterogeneity in tumors could not be included.\n* Patients who are about to receive or are receiving 24 weeks of PD1\u002FPDL1 antibody monothearpy and have not had the first efficacy assessment.\n* Archived tumor tissue samples or freshly obtained tumor tissue samples are available.\n* Female subjects of childbearing potential or male subjects with partners of childbearing potential agree to use highly effective contraception from 7 days before the first dose until 120 days after the last dose. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose.\n* Subjects have the ability and willingness to comply with the study protocol's visits, treatment plan, laboratory tests, and other study-related procedures.\n* For patients who are about to receive combination of Sintilimab, IBI310 and Lenvatinib. subjects should have good organ function within the first 7 days of initial dosing: HGB ≥ 80g\u002FL, NEU ≥ 1.0\\*10\\^9\u002FL, PLT ≥ 75\\*10\\^9\u002FL, Cr≤1.5×ULN or CrCl≥50mL\u002Fmin（Cockcroft-Gault method), TBiL ≤ 1.5×ULN, ALT and AST ≤3 ×ULN; urine protein \\\u003C2+; if urine protein ≥ 2+, 24 hour urinary protein quantity \\\u003C2g; INR, APTT, PT ≤ 1.5 ×ULN\n\nExclusion Criteria:\n\n* Distant metastasis;\n* Previous treatment including CTLA4 blockade;\n* Subjects with interstitial lung disease or a history of non-infectious pneumonia requiring oral or intravenous corticosteroid treatment.\n* Subjects with active autoimmune diseases requiring systemic treatment before the start of the study or those considered at risk of recurrence or planned treatment for autoimmune diseases as judged by the investigator. Except for these conditions: a) skin diseases that do not require systemic treatment (e.g., vitiligo, alopecia, psoriasis, or eczema); b) hypothyroidism caused by autoimmune thyroiditis, requiring stable doses of hormone replacement therapy; c) type 1 diabetes requiring stable doses of insulin replacement therapy; d) childhood asthma fully resolved with no need for intervention in adulthood; e) the investigator judges that the disease will not relapse without external triggering factors.\n* Subjects with a history of other malignant tumors within 5 years, excluding cured skin squamous cell carcinoma, basal cell carcinoma, non-invasive bladder carcinoma, localized low-risk prostate cancer (defined as stage ≤T2a, Gleason score ≤6, and prostate-specific antigen (PSA) ≤10 ng\u002FmL (if measured) in patients who have undergone curative treatment and have no biochemical recurrence of prostate-specific antigen (PSA)), in situ cervical\u002Fbreast carcinoma, or Lynch syndrome.\n* Subjects with uncontrolled comorbidities, including but not limited to: a) active HBV or HCV infection; b) subjects who are HBsAg positive and\u002For HCV antibody positive during screening must undergo HBV DNA and\u002For HCV RNA testing. Only subjects with HBV DNA ≤500 IU\u002FmL (or ≤2000 copies\u002FmL) and\u002For HCV RNA negative can be enrolled; HBV DNA monitoring will be at the discretion of the investigator based on the subject's condition during the trial; c) known HIV infection or AIDS history; d) active tuberculosis; e) uncontrolled hypertension (resting blood pressure ≥160\u002F100 mmHg), symptomatic congestive heart failure (NYHA II-IV), unstable angina or myocardial infarction within 6 months, or the presence of QTc prolongation or the risk of arrhythmia (baseline QTc \\>470 msec \\\u003CFridericia method correction\\>, refractory hypokalemia, long QT syndrome, atrial fibrillation with resting heart rate \\>100 bpm, or severe valvular heart disease); f) active bleeding that cannot be controlled after medical treatment.\n* History of allogeneic bone marrow or organ transplantation.\n* Previous history of allergic reactions, hypersensitivity reactions, or intolerance to antibody drugs (e.g., severe allergic reactions, immune-mediated hepatotoxicity, immune-mediated thrombocytopenia, or anemia).\n* Pregnant and\u002For lactating females.\n* For patients who are about to receive combination of Sintilimab, IBI310 and Lenvatinib: a) Subjects with a history of gastrointestinal perforation or fistula within 6 months before the first dose. If the perforation or fistula has been treated with resection or repair, and the disease is judged to be recovered or improved by the investigator, then enrollment is allowed. b) Subjects who have undergone major surgery within 28 days before the first dose (e.g., major abdominal or thoracic surgery; excluding drainage, diagnostic puncture, or peripheral vascular access replacement). c) Subjects who require systemic corticosteroids (≥10 mg\u002Fday prednisone or equivalent) or immunosuppressive therapy for a continuous 7-day period within 14 days before the first dose. Inhaled or locally applied steroids and physiological replacement doses of steroids due to adrenal insufficiency are allowed. Short-term (≤7 days) corticosteroids for prophylaxis (e.g., contrast dye allergy) or treatment of non-autoimmune diseases (e.g., delayed hypersensitivity reaction caused by exposure to allergens) are allowed. d) Toxicity from previous antitumor treatments has not recovered to Grade ≤2 (NCI-CTCAE v5.0) or baseline, except for alopecia, skin pigmentation (allowed at any level), and immune-related adverse reactions requiring physiological replacement (e.g., hypothyroidism, hypopituitarism, type 1 diabetes).",{"count":188,"type":21},34,[190],"PHASE2","This study intends to explore the role of PD1\u002FPDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR\u002FMSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability",[193,194,195,196],"Gastric Cancer","Colon Cancer","MSI-H","DMMR Cancer",[198,199,200],"Organ preservation","immunotherapy","anti-VEGF","2026-05-13",{"date":203,"type":32},"2026-05-15",{"date":205,"type":32},"2024-09-13",{"date":207,"type":21},"2029-06-01",{"name":38,"class":39},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":216,"maxAge":18,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":67},"100617985","the-effectiveness-of-guided-written-exposure-therapy-for-complex-ptsd-in-adolescents-100617985","NCT07325734","The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents","The Effectiveness of Guided Written Exposure Therapy for Complex PTSD in Adolescents: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged between 10 and 18 years;\n2. Meet the diagnostic or subclinical criteria for Complex PTSD (C-PTSD), defined as missing at most one symptom from either the PTSD or DSO clusters;\n3. Possess sufficient literacy and language skills to complete writing-based tasks;\n4. Be able to understand the study procedures and complete the required assessments;\n5. Provide written informed consent, with consent also obtained from their legal guardians.\n\nExclusion Criteria:\n\n1. Presence of a severe psychiatric disorder or neurodevelopmental disorder, such as schizophrenia, bipolar I disorder, autism spectrum disorder, intellectual disability, or other severe psychiatric conditions that would interfere with study participation;\n2. Presence of a severe physical illness that would impair the ability to engage in the intervention;\n3. Assessed as being at high suicidal risk (e.g., current suicidal ideation with intent or plan, recent suicide attempt within the past 12 months, or severe self-harm behaviors);\n4. Ongoing exposure to traumatic events;\n5. Currently receiving other trauma-focused psychological treatments.","10 Years",{"count":218,"type":21},130,[111],"This study aims to examine the effectiveness of group Guided Written Exposure Therapy for Complex Post-Traumatic Stress Disorder (GWE-C) among Chinese adolescents through a randomized controlled trial. A total of 120 participants will be recruited, with 60 randomized to the GWE-C group and 60 randomized to the supportive therapy (ST) group. The GWE-C intervention will consist of 7 to 10 group sessions. The primary outcome, assessed by the International Trauma Questionnaire (ITQ), will be measured at baseline, post-treatment, 1-month follow-up, and 3-month follow-up.",[222],"CPTSD, Compelx Post-traumatic Stress Disorder",[224,225,226],"adolescents","randomized controlled trial","Complex PTSD","2026-05-12",{"date":229,"type":32},"2026-05-14",{"date":231,"type":32},"2025-10-10",{"date":233,"type":21},"2026-12-25",{"name":38,"class":39},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":105,"sex":17,"minAge":216,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":128},"100640494","ai-gf-gnw-on-prolonged-grief-reactions-100640494","NCT07589088","AI-GF-GNW on Prolonged Grief Reactions","AI-Assisted Grief-Focused Guided Narrative Writing for Subclinical Prolonged Grief Disorder in Bereaved Chinese Adolescents: A Three-Arm Parallel Randomized Controlled Trial.","Inclusion Criteria:\n\n* Junior and senior high school students currently studying in Chinese Mainland, aged 10-19;\n* Between 6 and 60 months prior to the experimental period, experienced the death of a significant family member or close friend or close friend;\n* The total symptom score of PG-13-R is between 20-29 points;\n* Ability to write and understand written guidelines, to use the mobile phone to interact with AI;\n* Consent to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosed or previously diagnosed with mental illness\n* The bereavement time does not meet the time window\n* PG-13-R score is not within the range\n* At present, there is suicidal ideation or recent severe self harm behavior (Reynolds' Suicidal Ideation Questionnaire, SIQ-JR-4\\>0), and a crisis intervention hotline is provided when necessary.\n* Has received other grief counseling or is currently taking psychiatric medication within the past month","19 Years",{"count":244,"type":21},126,[111],"Prolonged Grief Disorder (PGD) is a severe, disabling condition characterized by intense yearning and difficulty accepting the reality of loss, which significantly impairs the academic and psychosocial functioning of bereaved adolescents. While Grief-Focused Cognitive Behavioral Therapy (GF-CBT) is effective, its high cost and resource-intensive nature limit its accessibility for adolescents in mainland China. Grief-Focused Guided Narrative Writing (GF-GNW) offers a scalable, low-cost alternative that facilitates memory integration.\n\nFurthermore, integrating Artificial Intelligence (AI) to provide personalized, structured feedback has the potential to simulate therapist functions and enhance intervention efficacy. However, the specific efficacy of AI-assisted feedback in this context remains empirically unvalidated.\n\nThis parallel randomized controlled trial aims to examine the effectiveness of AI-assisted GF-GNW (AI-GF-GNW) in treating Chinese adolescents (aged 10-19) with subclinical PGD, compared to a no-feedback NF-GF-GNW group and a free writing group. Primary outcomes include PGD symptom severity, while secondary outcomes assess depression, anxiety, and daily functioning. We hypothesize that both active intervention arms will significantly alleviate PGD and related symptoms compared to the free writing group, and that the AI-GF-GNW group will demonstrate a significantly greater reduction in symptoms and functional impairment than the NF-GF-GNW group.",[248,249,250,251,252],"Artificial Intelligence (AI)","Prolonged Grief Symptoms","Depression - Major Depressive Disorder","Anxiety","Disabilities","2026-05-09",{"date":203,"type":32},{"date":256,"type":21},"2026-05-25",{"date":258,"type":21},"2027-05",{"name":38,"class":39},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":67},"100628791","haic-plus-systemic-therapy-as-de-escalation-therapy-strategy-for-biliary-tract-cancer-100628791","NCT07466238","HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","HAIC Combined With Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer: A Conceptual Study","Inclusion Criteria:\n\n* Age: 18-80 years, both genders.\n* Diagnosis of biliary tract cancer (including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, and gallbladder cancer) and confirmed by histopathological or cytopathological examination.\n* Without distant metastasis or limited distant metastasis\n* Treatment-naive.\n* ECOG PS score \\\u003C 2.\n* Child-Pugh score: Class A or B (≤7).\n* Normal major organ function, meeting the following standards:(1) Blood routine examination:A. Hb≥90 g\u002FL;B. ANC≥1.5×10\\^9\u002FL;C. PLT≥75×10\\^9\u002FL;(2) Biochemical examination:A. ALB ≥30g\u002FL;B. ALT and AST\\\u003C5×ULN;C. TBiL ≤5×ULN;D. Creatinine ≤1.5×ULN;(3) Coagulation function:A. International normalized ratio (INR) ≤1.5×ULN;B. Activated partial thromboplastin time (APTT) ≤1.5×ULN.\n\nExclusion Criteria:\n\n* Coexistent or synchronous malignancies.\n* Distal cholangiocarcinoma.\n* Allergic to contrast agents or oxaliplatin.\n* Pregnant or lactating women.\n* Multiple extrahepatic metastases or combined malignant pleural and peritoneal effusions.\n* History of organ transplantation.\n* With infections requiring anti-infection treatment.\n* Severe and irreparable coagulation dysfunction.",{"count":268,"type":21},40,[111],"Biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis. Surgery is recognized as the only curative treatment for BTC, however, only about 20% BTC patients are eligible for curative resection since most patients with BTC are diagnosed at an advanced stage. The median overall survival (OS) in patients with unresectable BTC is typically less than 6 months. For patients with unresectable BTC, gemcitabine plus cisplatin (GemCis) had been recommended as the standard first-line treatment for many years. However, the objective response rate (ORR) of this regimen is only 26.1%, and the survival benefit remains limited, with a median OS of less than one year.\n\nIn recent years, two phase III trials (TOPAZ-1 and KEYNOTE-966) have demonstrated that combining immune checkpoint inhibitors (durvalumab or pembrolizumab) with the GemCis regimen could further prolong survival in patients with BTC, achieving a median OS of 12.9 months and 12.7 months, respectively. Based on this evidence, many guidelines worldwide had recommended GemCis plus durvalumab or pembrolizumab as the preferred standard first-line treatment for patients with unresectable BTC. However, survival benefits from this combination therapy remain relatively limited, and tumor response is suboptimal, with an ORR of only 26.7%-29%.\n\nHepatic arterial infusion chemotherapy (HAIC) enables continuous infusion of chemotherapeutic agents via the hepatic artery, significantly increasing local drug concentration at the tumor site, maximizing antitumor efficacy, and achieving a higher ORR (50%-60%) with substantial reduction in tumor burden. In recent years, HAIC has been increasingly used in the treatment of unresectable BTC, with its efficacy supported by many clinical studies.\n\nFirstly, HAIC provides survival benefits comparable to surgery in patients with multifocal intrahepatic cholangiocarcinoma (iCCA), and significantly outperforms systemic therapy. In 2022, a retrospective study enrolled 141 patients who received HAIC and 178 patients who underwent surgical resection from 12 centers. The results showed the median OS was 20.3 months in the HAIC group and 18.9 months in the resection group (P = 0.32), indicating comparable survival outcomes between HAIC and surgery. Given the risks of post-hepatectomy complications, HAIC may serve as an effective alternative treatment strategy for multifocal iCCA. Furthermore, for locally advanced unresectable iCCA, the results in a study in 2024 comparing HAIC with GemCis regimen chemotherapy revealed that although patients in the HAIC group had a higher tumor burden (proportion of multifocal disease: 73.4% vs. 55.3%, P = 0.023), the median OS in HAIC group remained significantly superior to that in the GemCis group (27.7 months vs. 11.8 months, P \\\u003C 0.001).\n\nSecondly, HAIC has also been demonstrated to be effective in treating perihilar cholangiocarcinoma (pCCA). In 2017, a single-arm, prospective phase II trial conducted in our center showed HAIC with oxaliplatin and fluorouracil yielded an ORR of 67.6%, a median progression-free survival (PFS) of 12.2 months, and a median OS of 20.5 months in treating perihilar cholangiocarcinoma (pCCA).\n\nFurthermore, HAIC also has clinical potential in treating advanced GBC. In 2021, a retrospectively study in our center enrolled 26 patients with advanced GBC who received HAIC with oxaliplatin and fluorouracil, of whom 23.1% had failed prior systemic therapy and 34.6% had contraindications to systemic treatment. The results showed that HAIC achieved a median PFS of 10 months and a median OS of 13.5 months, with an ORR of 69.2% and a disease control rate (DCR) of 92.3%.\n\nIn recent years, many studies have demonstrated that HAIC combined with systemic therapy could yield significant survival benefits in patients with unresectable BTC. A phase II clinical trial in 2022 evaluated the efficacy of HAIC with floxuridine plus systemic gemcitabine and oxaliplatin (GEMOX) in unresectable iCCA. The results showed that the combination therapy achieved a median PFS of 11.8 months and a median OS of 25 months, with a 6-month DCR of 84%, and 58% of patients achieved partial response (PR). Additionally, the association of benefit of combining HAIC with systemic chemotherapy and stage of BTC has been reported, and that patients with locally advanced cholangiocarcinoma may not derive such benefit from this combination. In 2025, a phase II clinical trial conducted in our center evaluated the efficacy and safety of HAIC (bevacizumab, oxaliplatin, and fluorouracil) combined with toripalimab as a first-line treatment for unresectable BTC. The results showed a median PFS of 13.2 months and a median OS of 19 months, with an ORR as high as 84.38%. Some patients achieved successful conversion resection following this combination therapy, and postoperative pathology confirmed pathological complete res",[272],"Biliary Tract Cancer (BTC)",[274,275,276],"biliary tract cancer","hepatic arterial infusion chemotherapy","systemic therapy","2026-05-05",{"date":279,"type":32},"2026-05-08",{"date":281,"type":32},"2026-03-31",{"date":283,"type":21},"2029-03-31",{"name":38,"class":39},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":128},"100614506","weekly-dynamics-of-psychopathological-and-symptom-networks-during-mindfulness-based-interventions-for-emotional-distress-100614506","NCT07280481","Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress","Inclusion Criteria:\n\n* experiencing emotional distress such as depression or anxiety (Kessler-10 score \\> 21)\n\nExclusion Criteria:\n\n* prior experience with mindfulness meditation\n* current self-harm or suicidal risk\n* bipolar disorder or schizophrenia\n* history of substance abuse\n* severe personal trauma history",{"count":292,"type":21},500,[111],"The goal of this clinical study is to learn how Mindfulness Intervention for Emotional Distress (MIED) helps people with emotional distress and how their symptoms and psychological patterns change over time.\n\nThe main questions it aims to answer are:\n\n* How do the relationships between emotions, thoughts, and behaviors change week by week during mindfulness training?\n* Which psychological skills, such as distress tolerance or cognitive flexibility, improve first and lead to later emotional relief? Two groups will be compared - one that takes part in an online mindfulness intervention and one that waits to join - to see how the intervention changes emotional and psychological networks over time.\n\nParticipants will:\n\n* Complete a 7-week online self-guided Mindfulness Intervention for Emotional Distress（iMIED） designed for people experiencing high emotional distress.\n* Fill out short weekly questionnaires about their emotions, thoughts, and behaviors before, during, and after the course (9 times in total).\n* Receive access to the mindfulness program after the study if they are in the wait-list group.\n\nThis study includes about 500 adults aged 18 and older who feel anxious, depressed, or emotionally distressed but have no major psychiatric disorders. By tracking weekly changes, the research aims to identify how mindfulness intervention leads to emotional improvement and which skills play the most important roles in that process.",[296,297],"Depression, Anxiety","Emotional Disorders","2026-04-24",{"date":300,"type":32},"2026-04-27",{"date":302,"type":32},"2025-11-16",{"date":149,"type":21},{"name":38,"class":39},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":105,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":315,"phases":4,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":128},"100584728","ctdna-mrd-monitoring-after-resection-in-gastric-cancer-100584728","NCT06893133","ctDNA-MRD Monitoring After Resection in Gastric Cancer","Personalized ctDNA-MRD in Recurrence Monitoring for Gastric Cancer Patients Undergoing Perioperative Treatment Combined With Curative Surgical Resection","MRD-GC","Inclusion Criteria:\n\n1. Patients have received neoadjuvant therapy and radical resection (R0).\n2. Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma.\n3. Patients must be able to provide sufficient fresh tissue\u002Fbiopsies or minimum 5-10 FFPE sections for NGS-WES analysis.\n4. Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point.\n\nExclusion Criteria:\n\n1. Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery.\n2. Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery.\n3. Other cases considered unsuitable for inclusion by researchers.",{"count":314,"type":21},110,"OBSERVATIONAL","Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.",[193],[319,320,193],"ctDNA","MRD","2026-04-19",{"date":323,"type":32},"2026-04-21",{"date":325,"type":32},"2025-04-08",{"date":327,"type":21},"2027-04-30",{"name":38,"class":39},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":346,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":128},"100628166","the-step-mied-trial-digital-stepped-care-for-emotional-disorders-100628166","NCT07458100","The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders","Effectiveness and Cost-effectiveness of a Digital Stepped-care Mindfulness Intervention for Recovery From Emotional Disorders: a Multicentre Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age: 18-65 years.\n2. Diagnosed with an emotional disorder by a outpatient psychiatrist, including depressive disorders, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder), obsessive-compulsive disorder, post-traumatic stress disorder, and eating disorders (e.g., anorexia nervosa, bulimia nervosa).\n3. Symptom severity meeting the threshold: PHQ-9 score ≥10 or GAD-7 score ≥8.\n\nExclusion Criteria:\n\n1. Current diagnosis of psychotic disorders or bipolar disorder.\n2. Current organic mental disorders, pervasive developmental disorders, severe cognitive impairment, or substance use disorders.\n3. Current suicide risk (PHQ-9 item 9 score \\>2).\n4. Antisocial personality disorder.\n5. Severe medical illnesses that may affect intervention participation or require recent hospitalization.\n6. Previous participation in a systematic 8-week mindfulness course.\n7. Inability to access the internet.",{"count":337,"type":21},464,[111],"The goal of this clinical trial is to evaluate the effectiveness and cost-effectiveness of a digital mindfulness-based intervention in adults (aged 18-65) diagnosed with emotional disorders like depression or anxiety. The main questions it aims to answer are:\n\n* Does adding a digital mindfulness intervention to usual care help people recover from emotional disorders faster and more sustainably over two years?\n* Is this combined approach more cost-effective than usual care alone? Researchers will compare the group receiving the digital mindfulness intervention plus their usual treatment to the group receiving only their usual treatment to see if the intervention leads to better long-term recovery and represents good value for money.\n\nParticipants in the intervention group will:\n\n* Attend eight weekly 2-hour online group mindfulness sessions.\n* Use a WeChat mini-program for 49 days of guided mindfulness exercises and daily tasks.\n* Patients who have not achieved reliable recovery after group retraining voluntarily participate in individual UP\\&MIED counseling.\n* Complete regular questionnaires and interviews over two years to track their progress.\n\nAll participants will continue to receive their usual medical care from their doctors throughout the study.",[297,341,342,343,344,345],"Depressive Disorder","Anxiety Disorders","Obsessive-Compulsive Disorder","Post-Traumatic Stress Disorder, PTSD","Eating Disorders",[347,348,349,225,350,297],"Cost-effectiveness","Mindfulness","Recovery","stepped-care","2026-04-18",{"date":323,"type":32},{"date":354,"type":32},"2026-03-23",{"date":356,"type":21},"2028-05",{"name":38,"class":39},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":366,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":128},"100632856","fangshan-active-nutrition-initiative-100632856","NCT07519122","Fangshan Active Nutrition Initiative","Research on Weight Management of School-age Children in Fangshan District Based on a Digital Intelligence Platform","FAN","Inclusion Criteria:\n\n* Schools will be selected based on the consent of primary leadership, demonstrated cooperation, and availability of necessary personnel (e.g., school health professionals).\n* Classes will be limited to grades 2 and 3, with teachers showing strong willingness to collaborate.\n* Both parental informed consent and child assent are required for participation.\n\nExclusion Criteria:\n\n* Schools will be excluded if they cater to special populations (e.g., schools for children with disabilities), are involved in other obesity-related interventions within the specified timeframe, or plan to close or relocate within two years.\n* Children will be excluded if they have histories of major organ diseases (e.g., cardiac, pulmonary, hepatic, or renal conditions), special diets (e.g., vegetarian), pathological eating disorders, physical limitations affecting activity, or obesity due to endocrine disorders or medication side effects.","8 Years","9 Years",{"count":369,"type":21},1400,[111],"The goal of this study is to evaluate the effectiveness of a school-based weight management intervention delivered through a digital platform (WeChat) in preventing excessive weight gain and improving health behaviors in school-aged children in Fangshan District, Beijing. The main questions it aims to answer are:\n\nDoes the intervention group show a significantly lower mean increase in BMI, body fat percentage, and waist circumference compared to the control group? Does the intervention group show a significantly lower obesity rate and new obesity incidence compared to the control group? Does the intervention group show significant improvements in healthy eating, sedentary behavior, sleep, physical activity, and physical fitness test scores compared to the control group? Researchers will compare children in intervention schools (who receive the multi-level intervention targeting students, families, and schools, supported by a digital platform for behavior monitoring and feedback) to children in control schools (who do not receive the intervention during the study period).\n\nParticipants in the intervention group will: (1) attend 10 student health education sessions; (2) have their physical activity at school increased to 60 minutes\u002Fday of moderate-to-vigorous activity; (3) have parents attend health education lectures and use a WeChat platform to receive health information, log child health data, and receive automated feedback; (4) have their height, weight, waist circumference, and body composition measured monthly by school health staff; and (5) be followed with assessments at 6, 12, and 24 months.",[373],"Childhood Weight Management",[375,376,377,378,379],"School-aged","Intervention","Overweight","Obesity","Children","2026-04-12",{"date":382,"type":32},"2026-04-15",{"date":384,"type":21},"2026-04-20",{"date":386,"type":21},"2029-04-30",{"name":38,"class":39},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":395,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":67},"100631357","digital-health-intervention-for-early-identification-and-prevention-of-gestational-diabetes-mellitus-100631357","NCT07499622","Digital Health Intervention for Early Identification and Prevention of Gestational Diabetes Mellitus","A Multicenter Randomized Controlled Trial of a Digital Health Intervention for Risk Identification, Intelligent Early Warning, and Prevention of Gestational Diabetes Mellitus Based on Multi-Source Data Integration","Inclusion Criteria:\n\n* Pregnant women in early pregnancy (within 13 weeks and 6 days of gestation)\n* Planned delivery at a participating study hospital\n* Age 18 years or older\n* Singleton pregnancy\n* Identified as high risk for gestational diabetes mellitus by the study risk assessment model\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* • Pre-pregnancy diabetes mellitus or overt diabetes diagnosed at the first antenatal visit (fasting blood glucose greater than or equal to 7.0 mmol\u002FL)\n\n  * Pre-existing hypertension, autoimmune disease, major infection, or severe liver or kidney disease\n  * Use of medications that affect glucose metabolism, such as corticosteroids or metformin\n  * Severe psychiatric disorders\n  * Inability or unwillingness to comply with study procedures","FEMALE",{"count":397,"type":21},1200,[111],"This study aims to develop and evaluate an early risk identification and digital health intervention strategy for gestational diabetes mellitus (GDM) among pregnant women in China. Gestational diabetes mellitus is a common pregnancy complication associated with adverse maternal and neonatal outcomes, including excessive gestational weight gain, macrosomia, cesarean delivery, and increased long-term risk of metabolic disorders in both mothers and offspring.\n\nThe study includes two components. First, retrospective multi-source clinical data from maternal health records will be used to develop and validate a risk prediction model for early identification of pregnant women at high risk of GDM. Second, pregnant women identified as high risk in early pregnancy will be enrolled in a multicenter randomized controlled trial and assigned to either a digital health intervention group or a usual care group. The intervention includes online health education, individualized lifestyle guidance, behavioral self-management tools, and interactive consultation through a digital platform. The primary outcome is the incidence of GDM diagnosed during pregnancy. Secondary outcomes include gestational weight gain, cesarean delivery, macrosomia, and other maternal and neonatal outcomes.\n\nThis study is expected to provide evidence for improving early risk assessment, intelligent warning, and prevention strategies for GDM in the context of maternal health management in China.",[401],"Gestational Diabetes Mellitus (GDM)","2026-03-24",{"date":404,"type":32},"2026-03-30",{"date":406,"type":21},"2026-06",{"date":65,"type":21},{"name":38,"class":39},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":22,"phases":419,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":128},"100630363","phase-1-the-phase-i-study-of-sig001-antibody-on-cancer-therapy-100630363","NCT07486700","The Phase I Study of SIG001 Antibody on Cancer Therapy.","An Open-label, Phase I, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SIG001 in Subjects With Advanced Solid Tumors.","Inclusion Criteria:\n\n* Subjects must meet all of the following criteria to be eligible for this clinical study:\n\n  1. The subject must fully understand the requirements of this study and voluntarily sign a written informed consent form. They must also be able to comply with the study's medication regimen as well as all related procedures and assessments;\n  2. Age must be \\>=18 and \\\u003C=75 years old, with no gender restriction;\n  3. Subjects must have locally advanced, recurrent, or metastatic malignant tumors that have failed standard treatment or are not tolerant to it, and for which there is no effective standard treatment option. Histological or cytological confirmation is required;\n  4. According to RECIST v1.1, the subject must have at least 1 measurable target lesion. At baseline, the lesion must be accurately measurable by computed tomography (CT) or magnetic resonance imaging (MRI) - preferably with intravenous contrast agent. The long diameter of non-lymph node lesions must be ≥10 mm, and the short axis of lymph node lesions must be \\>=15 mm. The lesion must be suitable for repeated and accurate measurements. If a lesion in a previously irradiated area shows clear progression, it can also be considered a measurable target lesion;\n  5. The expected survival time must be \\>=12 weeks;\n  6. The Eastern Cooperative Oncology Group performance status score must be 0 or 1;\n  7. Subjects must have adequate function of vital organs at the time of screening. This requires that no blood transfusions, hematopoietic stimulants, or human albumin preparations have been used within 14 days prior to screening. The specific criteria are as follows:\n\n  \u003C!-- -->\n\n  1. Blood tests: Absolute neutrophil count \\>=1.5 × 10\\^9\u002FL; Platelet count \\>=75 × 10\\^9\u002FL; Hemoglobin \\>=90 g\u002FL;\n  2. Liver function: Serum TBIL \\\u003C=1.5 × ULN. For patients with liver metastases or Gilbert's syndrome, TBIL \\\u003C=3 × ULN. For subjects without liver metastases, ALT and AST \\\u003C=2.5 × ULN; for those with liver metastases, ALT and AST \\\u003C=5 × ULN;\n  3. Coagulation function: Activated partial thromboplastin time and International normalized ratio \\\u003C=1.5 × ULN (for subjects on anticoagulant therapy, these values must be within the therapeutic range).\n  4. Renal function: Creatinine clearance rate \\>=60 mL\u002Fmin, calculated using the Cockcroft-Gault formula;\n  5. Cardiac function: Echocardiography shows left ventricular ejection fraction greater than 50%; 8. Female subjects of childbearing age must have a negative pregnancy test within 7 days before receiving the study drug for the first time. Eligible male and female subjects must agree to use reliable contraceptive methods (hormonal, barrier methods, or abstinence) during the study and for at least 6 months after the last dose of the drug. Eligible subjects are defined as being sexually mature and biologically capable of reproducing.\n\nExclusion Criteria:\n\n* Subjects will be excluded if they meet any of the following criteria:\n\n  1. SIG001 is administered during the washout period following previous antineoplastic therapy (4 weeks or 5 half-lives after the last dose, whichever is shorter);\n  2. Received radiotherapy within 28 days prior to the first dose of SIG001;\n  3. Acute toxicity resulting from previous antineoplastic therapy had not resolved to NCICTCAE 5.0 version grade ≤1 or to the baseline level specified in the inclusion criteria 4 weeks before the first dose of SIG001 (excluding hair loss or fatigue);\n  4. Had a history of other malignant tumors within 5 years prior to the first dose (except for non-melanoma skin basal cell carcinoma or squamous cell carcinoma that has been cured with no evidence of recurrence, breast\u002Fcervical carcinoma in situ, superficial bladder carcinoma, and other in situ cancers);\n  5. Subjects with any of the following cardiovascular diseases:\n\n  \u003C!-- -->\n\n  1. Symptomatic heart failure (New York Heart Association functional class \\>=2, see Appendix 4);\n  2. Uncontrolled hypertension despite standard treatment (systolic blood pressure \\>=160 mmHg or diastolic blood pressure \\>=100 mmHg);\n  3. Resting mean corrected QT interval \\> 470 ms on a 12-lead electrocardiogram (QTc, using Fridericia's correction formula) on three repeated measurements. Various clinically significant arrhythmias, conduction abnormalities, and resting ECG abnormalities, such as complete left bundle branch block, third-degree block, second-degree block, and PR interval \\> 250 ms. Factors that may increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome or sudden death before age 40, and use of medications known to prolong QTc;\n  4. Acute coronary syndrome\u002Facute myocardial infarction, unstable angina pectoris, percutaneous coronary intervention or coronary artery bypass grafting within 6 months prior to screening;\n  5. Any cause of cardiomyopathy;\n  6. Clinically significant valvular heart disease;\n  7. History of atrial or ventricular arrhythmias that require treatment; subjects with atrial fibrillation and well-controlled ventricular rate may be enrolled;\n  8. Transient ischemic attack or stroke within 6 months prior to screening; 6. Subjects with infectious diseases, including;\n\n  \u003C!-- -->\n\n  1. Acute or chronic active hepatitis B, defined as positive for hepatitis B surface antigen (HbsAg) and\u002For hepatitis B core antibody (HbcAb) with HBV DNA \\>=100 IU\u002FmL;\n  2. Acute or chronic active hepatitis C, i.e., positive for HCV antibodies with HCV-RNA levels above the upper limit of the central reference range;\n  3. HIV-infected individuals (positive for HIV 1\u002F2 antibodies);\n  4. Active syphilis or active pulmonary tuberculosis; 7. Subjects with primary central nervous system tumors, meningeal metastases, spinal cord compression, or brainstem metastases; those with untreated brain metastases or symptomatic\u002Fstable conditions can be enrolled after at least 4 weeks of stable treatment; 8. Uncontrolled comorbidities, such as:\n\n  \u003C!-- -->\n\n  1. Severe infections within 4 weeks prior to study initiation, including hospitalization due to infection, bacteremia, or severe pneumonia; subjects with uncontrolled active infections during screening can be enrolled if they receive prophylactic antibiotics (e.g., for urinary tract infections or chronic obstructive pulmonary disease);\n  2. History of interstitial lung disease, unresolved radiation pneumonitis, acute episodes or progressive worsening of pulmonary symptoms at baseline, or factors that increase the risk of interstitial lung disease and pose a safety risk to the subject as assessed by the investigator;\n  3. Severe malnutrition requiring intravenous nutrition; subjects whose malnutrition has been corrected and stabilized for more than 4 weeks prior to the first dose can be enrolled;\n  4. Tumors invading vital organs or blood vessels, which may significantly increase treatment risk or affect efficacy assessment; subjects with a risk of esophagotracheal fistula or esophagothoracic fistula, or those within 4 weeks of esophageal or tracheal stent placement (subjects with stable conditions for more than 4 weeks can be enrolled);\n  5. History of gastrointestinal perforation and\u002For fistula within 6 months prior to screening;\n  6. Presence of uncontrolled effusions requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Subjects without the need for drainage or with no significant increase in effusion volume after 3 days of drainage cessation can be enrolled).\n\n  9\\. Subjects who are expected to receive other antineoplastic treatments during the study period (palliative radiotherapy is allowed); 10. Subjects who have participated in clinical studies within 4 weeks prior to the first dose or plan to participate in other clinical studies during the study period; 11. Subjects who have received live vaccines within 4 weeks prior to the first dose; 12. Allergy to SIG001 or its components; 13. Pregnant women, lactating women, or women who plan to become pregnant during the study period; 14. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; 15. Subjects who have received systemic immunosuppressive therapy for autoimmune diseases within 2 years prior to dosing are excluded, except in the following cases:\n  1. Inhaled, topical, or intramuscular steroid use;\n  2. Systemic corticosteroids (dose not exceeding 10 mg\u002Fday of prednisone or equivalent);\n  3. Steroids used as premedication for hypersensitivity reactions (e.g., premedication for CT scans).\n\n  16\\. Subjects with a history of mental disorders and those taking medication for treatment; 17. Subjects with a history of drug abuse or substance use; 18. Subjects who, in the judgment of the investigator, have other factors that may affect the study results or interfere with their participation in the entire study, including past or current health conditions, treatment or laboratory test abnormalities, and those who are unwilling to comply with the study procedures and requirements.","75 Years",{"count":418,"type":21},66,[50],"The goal of this clinical trial is to learn the safty characteristics of SIG001 Mab in cancer patients; It will also determine the Recommended Phase II dose of SIG001 Mab on cancer treatment, and pharmacological characteristics of SIG001. The main questions it aims to answer are:\n\nWhat is the safety and tolerability of SIG001 in patients with advanced solid tumors ? What is the Recommended Phase II dose of SIG001? What is the PK\u002FPD characteristics of SIG001 in cancer patients? What is the antitumor activity of SIG001 in cancer patients? What is the immunogenicity of SIG001 in cancer patients? What is the relationship between the exposure\u002Fdose of SIG001 and its safety as well as clinical efficacy? What is the expression levels of potential biomarkers (such as SIG), if applicable, and analyze their correlation with drug exposure, efficacy, and safety? What is event-related endpoints such as the Duration of Response and Progression-Free Survival in patients treated with SIG001?\n\nThis will be a single-armed study.\n\nParticipants will:\n\nIntravenously Inject SIG001 every two weeks, for 4 weeks Visit the clinic on the 14th day, 30th day, and 90th day afer the last injection. Then visit the clinic for every 12 weeks.",[422],"Neoplams",[424,425,426],"neoplams","tumor IgG","sialylated IgG","2026-03-17",{"date":429,"type":32},"2026-03-20",{"date":431,"type":21},"2026-03",{"date":433,"type":21},"2028-07",{"name":38,"class":39},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":443,"briefSummary":444,"conditions":445,"keywords":446,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":453,"leadSponsor":455,"locationsCount":456},"100629888","efficacy-and-mechanisms-of-escitalopram-in-drug-nave-first-episode-major-depressive-disorder-100629888","NCT07480525","Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder","Inclusion Criteria:\n\n1. Aged 18-65 years (including 18 and 65), no gender restriction, Han Chinese ethnicity.\n2. Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), confirmed by the Mini-International Neuropsychiatric Interview, version 5.0 (MINI).\n3. Outpatients or inpatients; Hamilton Depression Rating Scale-17 items (HAMD-17) score ≥17; Hypomania Checklist-32 (HCL-32) score ≤13; and Clinical Global Impressions-Severity (CGI-S) score ≥4.\n4. First depressive episode (duration ≤3 months), with no use of antidepressants or other psychotropic medications in the past 3 months.\n5. Written informed consent obtained from the patient.\n\nExclusion Criteria:\n\n1. Meet DSM-IV diagnostic criteria other mental disorders, including schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive disorder, etc..\n2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness;\n3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury;\n4. Have attempted suicide within the past 3 months, or currently present a high suicide risk, defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) item 10 score ≥5.\n5. Are pregnant or breastfeeding, cannot use reliable contraception during the study, or plan to conceive (or impregnate a partner) within 3 months after study initiation.\n6. Have known allergies to escitalopram oxalate or its excipients.\n7. Are currently taking medications that may interfere with the evaluation of escitalopram efficacy.\n8. Have participated in another drug clinical trial within the past 3 months.\n9. Have contraindications to MRI scanning, such as metal implants or claustrophobia.\n10. Considered unsuitable for study participation by the investigators for any other reason.",{"count":442,"type":21},200,[111],"The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression.\n\nThis multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.",[250],[447,448],"depression","antidepressant","2026-03-14",{"date":451,"type":32},"2026-03-18",{"date":429,"type":21},{"date":454,"type":21},"2026-12-31",{"name":38,"class":39},5,{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":22,"phases":466,"briefSummary":467,"conditions":468,"keywords":470,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":4},"100627853","phase-1-intraperitoneal-px-in-combination-with-nab-paclitaxel-in-patients-with-peritoneal-metastatic-mucinous-adenocarcinoma-100627853","NCT07454031","Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma","An Investigator-Initiated Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of sex;\n* Histologically confirmed peritoneal metastatic mucinous adenocarcinoma;\n* Considered suitable for intraperitoneal therapy based on investigator assessment;\n* ECOG performance status 0-2;\n* Adequate organ function confirmed by laboratory tests within 7 days prior to enrollment:\n* Hematology: ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 100 × 10⁹\u002FL; Hb ≥ 85 g\u002FL; Liver function: TBIL ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome);AST\u002FALT ≤ 3 × ULN (≤ 5 × ULN in patients with liver metastases); Renal function: creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault) or serum creatinine ≤ 1.5 × ULN; Coagulation: PT, INR, and APTT ≤ 1.5 × ULN;\n* Life expectancy ≥ 3 months;\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Planned concomitant systemic anti-tumor therapy during intraperitoneal treatment;\n* Massive ascites not expected to be adequately drained prior to dosing;\n* Chemotherapy or radiotherapy within 4 weeks prior to enrollment (≥ 6 weeks for nitrosoureas or mitomycin C);\n* Pregnancy or lactation, or unwillingness to use effective contraception;\n* Severe abdominal infection or gastrointestinal obstruction;\n* Known peritoneal adhesions deemed unsuitable for catheter placement;\n* Active bleeding, uncorrected coagulation disorders, or inability to safely interrupt therapeutic anticoagulation;\n* Known hypersensitivity to PX, nab-paclitaxel, or excipients;\n* Pre-existing ≥ Grade 2 peripheral sensory neuropathy;\n* Severe or uncontrolled comorbidities that may increase study risk or interfere with evaluation;\n* Active or severe autoimmune disease, or ongoing systemic immunosuppressive therapy;\n* Positive for HBsAg, anti-HCV, syphilis antibody, or HIV antibody;\n* Psychiatric or cognitive disorders affecting compliance;\n* Any other condition deemed unsuitable by the investigator.",{"count":465,"type":21},22,[50],"To evaluate the safety and tolerability of intraperitoneal PX in combination with nab-paclitaxel in patients with peritoneal metastatic mucinous adenocarcinoma, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).",[469],"Peritoneal (Metastatic) Cancer",[471,472,473,474],"peritoneal adenocarcinoma","PX","nab-paclitaxel","intraperitoneal injection·","2026-03-11",{"date":477,"type":32},"2026-03-13",{"date":479,"type":21},"2026-03-15",{"date":481,"type":21},"2027-12-31",{"name":38,"class":39},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":4},"100621650","blended-resources-for-integrated-diabetes-guidance-and-empowerment-100621650","NCT07373379","Blended Resources for Integrated Diabetes Guidance and Empowerment","Effectiveness and Implementation of an AI-Driven Blended Care Model for Type 2 Diabetes Management in Primary Care: A Single-Blind, Cluster Randomized Controlled Trial in Zhangjiagang, China","BRIDGE","Inclusion Criteria:\n\n* Aged 18 to 70 years (inclusive).\n* Glycosylated hemoglobin (HbA1c) level ≥ 6.5%.\n* Resided in the local area for at least 6 months.\n* Capable of using a smartphone to take photos and use the WeChat mini-program.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with Type 1 diabetes, gestational diabetes, or secondary diabetes.\n* Presence of severe diabetic complications.\n* Received radiotherapy or chemotherapy within the past 6 months.\n* Diagnosed with severe intellectual disabilities, Alzheimer's disease, or other serious psychiatric disorders.\n* Current participation in other research projects that may affect the results of this study.\n* Presence of other severe disabilities or medical conditions deemed unsuitable for participation by the investigators.","70 Years",{"count":397,"type":21},[111],"The goal of this cluster randomized clinical trial is to learn if an AI-enabled blended care model (the BRIDGE program) works to treat type 2 diabetes in adults. It will also learn about the cost-effectiveness and implementation feasibility of this model in primary care settings. The main questions it aims to answer are:\n\nDoes the AI-driven intervention lower HbA1c levels (blood sugar) compared to standard care?\n\nDoes this model improve participants' quality of life, self-management behaviors, and digital literacy?\n\nResearchers will compare the \"Diet-Medicine Companion\" (Shi Yi Ban Lv) mini-program combined with family doctor support to standard community care to see if the blended care model works to manage diabetes.\n\nParticipants will:\n\nUse the \"Diet-Medicine Companion\" mini-program to upload diet photos daily and receive AI feedback for 6 months\n\nReceive periodic guidance and phone reminders from case administrators (family doctors)\n\nComplete questionnaires and blood tests (HbA1c) at baseline, 3 months, and 6 months",[496],"Type 2 Diabetes Mellitus",[496,498,499,500],"digital health","AI","blended care","2026-02-19",{"date":503,"type":32},"2026-02-23",{"date":505,"type":21},"2026-03-01",{"date":507,"type":21},"2026-10-30",{"name":38,"class":39},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":395,"minAge":18,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":22,"phases":519,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":534},"100615607","pregnancy-salt-substitution-trial-for-hypertensive-disorders-of-pregnancy-prevention-preg-salt-100615607","NCT07294807","Pregnancy Salt Substitution Trial for Hypertensive Disorders of Pregnancy Prevention (PREG-Salt)","Effectiveness, Safety, and Cost-effectiveness of Salt Substitution in High-risk Pregnant Women for the Prevention of Hypertensive Disorders of Pregnancy","PREG-Salt","Inclusion Criteria:\n\n1. Singleton pregnancy with a viable fetus at ≤16 weeks of gestation.\n2. Meets at least one of the following criteria (enrolled sequentially):\n\n   1. Systolic Blood Pressure (SBP) ≥130 mmHg and \\\u003C160 mmHg at enrollment, OR current monotherapy with antihypertensive medications such as labetalol or nifedipine (priority enrollment).\n   2. At least one of the following 4 items: advanced maternal age (≥35 years), pre-pregnancy obesity (BMI ≥28 kg\u002Fm²), history of preeclampsia, or pre-existing type 1 or type 2 diabetes.\n   3. At least two of the following 5 items: history of adverse pregnancy outcome (e.g., fetal death, placental abruption, fetal growth restriction), personal history of gestational hypertension or family history of preeclampsia (mother or sister), history of gestational diabetes, obstructive sleep apnea, or pre-pregnancy overweight (BMI 24-28 kg\u002Fm²).\n3. Routinely eats at least two meals per day at home (including meals brought from home).\n4. Able to attend regular antenatal check-ups and is expected to complete the study follow-up.\n5. Provides written informed consent. -\n\nExclusion Criteria:\n\n1. SBP ≥160 mmHg or Diastolic Blood Pressure (DBP) ≥110 mmHg at enrollment.\n2. Conditions or history associated with high uterine tension (e.g., polyhydramnios, macrosomia, hydatidiform mole); autoimmune diseases (e.g., systemic lupus erythematosus, antiphospholipid syndrome).\n3. History of chronic kidney disease, OR any antenatal check-up with a confirmed estimated Glomerular Filtration Rate (eGFR) \\\u003C70 ml\u002Fmin\u002F1.73m², OR dipstick urine protein ≥2+.\n4. Diagnosed hyperkalemia.\n5. History of hypotension or syncope.\n6. A household member who shares meals has a confirmed diagnosis of chronic kidney disease or hyperkalemia.",{"count":518,"type":21},3200,[111],"The PREG-Salt study is to evaluate the effect, safety and cost-effectiveness of low-sodium salt in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. The study will recruit about 3,200 participants from approximately 100 hospitals across multiple provinces in China. Eligible pregnant women (≤16 weeks of gestation) will be randomly assigned in a 1:1 ratio to the following 2 groups:\n\n1. Salt subsittute(intervention);\n2. Usual salt (control) .\n\nThe intervention will last until delivery. The study employs an adaptive two-phase design. An interim analysis after the first phase (n=400) will inform whether the trial continues into the second phase and if any adjustments to the sample size are needed. The primary outcomes are:\n\nPhase 1: The mean systolic blood pressure across antenatal visits (excluding the last week before delivery).\n\nPhase 2: New-onset hypertensive disorders of pregnancy and related adverse events from randomization to delivery.",[522],"Hypertensive Disorders of Pregnancy",[524,525],"Sodium reduction","Pregnancy disorders","2025-12-19",{"date":528,"type":32},"2025-12-29",{"date":530,"type":21},"2025-12-25",{"date":532,"type":21},"2027-12-25",{"name":38,"class":39},107,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":542,"targetDuration":4,"studyType":22,"phases":544,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":128},"100545315","early-phase-1-a-clinical-study-on-evaluating-intravenous-administration-of-idov-safe-100545315","NCT06380309","A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE","An Open Label, Dose-escalation and Extension, Phase I Clinical Study on Evaluating Safety, Tolerability and Pharmacodynamics of Intravenous Administration of IDOV-SAFE in Patients With Advanced Malignant Solid Tumors Who Have Failed in Standard Treatment.","Inclusion Criteria:\n\n1\\. Be fully aware of this study and voluntarily sign ICF. 2. Age range from 18 to 75 years old at the time of screening, gender is not limited.\n\n3\\. At the time of screening, patients with advanced malignant digestive system tumors confirmed by histology or cytology, including MSS type colorectal cancer, bile duct cancer, stomach cancer, esophageal cancer, liver cancer, etc.\n\n4\\. At the time of screening, the disease has progressed after or during standard treatment; Subjects with advanced malignant digestive system tumors with no standard treatment currently available, intolerance to chemotherapy, or greater than or equal to progression after 2-line system therapy.\n\n1. Be fully aware of this study and voluntarily sign ICF.\n2. Age range from 18 to 70 years old at the time of screening, gender is not limited.\n3. At the time of screening, patients with advanced malignant digestive system tumors confirmed by histology or cytology, including MSS type colorectal cancer, bile duct cancer, stomach cancer, esophageal cancer, liver cancer, etc.\n4. At the time of screening, the disease has progressed after or during standard treatment; Subjects with advanced malignant digestive system tumors with no standard treatment currently available, intolerance to chemotherapy, or greater than or equal to progression after 2-line system therapy.\n5. When screening, the ECOG score of physical strength score is 0 or 1.\n6. Life expectancy assessed by the investigator at the time of screening was ≥3 months.\n7. Subjects had adequate organ function at baseline:\n\n   a) Bone marrow function (no growth factor support therapy or component transfusion within 14 days prior to screening) : i. Neutrophil absolute value (ANC) ≥1.5×109\u002FL; ii. Hemoglobin (HB) ≥90g\u002FL; iii. Platelet count (PLT) ≥75×109\u002FL; b) Liver function: i. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 times the upper limit of normal (ULN) (ALT and AST≤ 3 times ULN for liver metastasis or hepatocellular carcinoma); ii. Total blood bilirubin ≤ 1.5 ULN (in subjects with liver metastasis or hepatocellular carcinoma or Gilbert syndrome or familial benign nonbinding hyperbilirubinemia, the acceptable range of this indicator is ≤2.5 ULN); c) Renal function: serum creatinine ≤ 1.5x ULN or creatinine clearance ≥50mL\u002Fmin;\n8. Fertile female subjects must have negative blood beta-HCG test results within 7 days prior to enrollment.\n9. Subjects must agree to use highly effective contraception for at least 90 days from the start of the ICF to the end of the study.\n10. At least one measurable lesion according to RECIST v1.1 criteria, The target lesion had not been treated with radiotherapy or had definite radiographic progression after previous radiotherapy.\n\nExclusion Criteria:\n\n1. At the time of screening, advanced malignant tumors have a chance of being cured by radical treatment.\n2. Asymptomatic brain metastases such as untreated ones at the time of screening; Subjects with symptomatic central nervous system (CNS) metastatic or cancerous meningitis; Or there was other evidence of uncontrolled central nervous system or meningeal metastases in subjects who were judged by the investigator to be unsuitable for enrollment.\n3. Prior to enrollment, there was severe chronic or active infection: active hepatitis B (HbsAg positive, HBV DNA test value greater than the upper limit of normal); Active hepatitis C (those with positive anti-HCV antibodies are further tested positive for HCV RNA); A known history of immunodeficiency virus (HIV) disease or a positive HIV antibody test; Other conditions requiring systemic anti-infective treatment in the 4 weeks prior to initial use of the investigational drug include, but are not limited to, hospitalization for infectious complications, bacteremia, severe pneumonia, or active tuberculosis.\n4. At the time of screening, patients had a history of active autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc., or were receiving long-term systemic steroids (prednisone \\>10mg\u002F day or equivalent doses of the same drug) or any other form of immunosuppressant therapy within 14 days prior to the first use of the study drug.\n5. Have received allogeneic tissue or solid organ transplantation.\n6. There is evidence of clinically significant immunodeficiency, such as primary immunodeficiency status, such as severe combined immunodeficiency disease (SCID); Combined with opportunistic infections.\n7. Anticoagulants or antiplatelet drugs should be used before injection and should not be interrupted, including: aspirin should not be stopped within 7 days before injection; Coumarin that cannot be stopped within 7 days prior to injection; Direct thrombin inhibitors (such as dabigatrun) or direct factor Xa inhibitors (such as rivaroxaban, apixaban, and neperoxaban) that cannot be discontinued within 4 days prior to injection; Low molecular weight heparin (LMWH) should not be stopped within 24 hours before injection, and ordinary heparin (UFH) should not be stopped more than 4 hours before injection.\n8. Have a history of severe cardiovascular and cerebrovascular disease, including but not limited to: congestive heart failure ≥II heart function grade of the New York Heart Association (NYHA); Left ventricular ejection fraction (LVEF) \\\u003C50%; QT interval (QTcF) \\>470ms as corrected by the Fridericia method or prolonged QT interval syndrome; Acute coronary syndrome, aortic dissection, severe arrhythmia, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events occurred within 6 months before first administration; The presence of uncontrolled hypertension (systolic blood pressure \\>140mmHg or diastolic blood pressure \\>90mmHg). Subjects with a history of hypertension are admitted to the study if their blood pressure is controlled below this standard and maintained with antihypertensive therapy.\n9. Received treatment with other methods, including but not limited to chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy, etc., within 4 weeks prior to the first use of the investigational drug.\n10. Other diseases or abnormalities assessed by the investigator as unsuitable for participation in the study.\n11. Vaccination against smallpox or monkeypox within 10 years before the first use of study drug.\n12. Allergy to macromolecular antibody drugs or small molecule TKI drugs.",{"count":543,"type":21},89,[545],"EARLY_PHASE1","Subjects were Chinese patients with histologically or cytologically confirmed advanced malignant solid tumors (mainly focused on MSS type colon and rectal cancer) who had failed standard systemic therapy and were inoperable.\n\nThe first stage was the dose escalation stage, which was divided into 4 dose groups according to the \"3+3\" dose escalation principle. One patient was enrolled in the first dose group, and 3-6 patients were enrolled in each of the latter three dose groups, with a total of 10-19 patients enrolled.\n\nThe second stage is the security extension stage, which is selected by SMC 1-2 dose cohorts were expanded for safety and divided into three cohorts in total(IIA, IIB, IIC) to explore the safety of sequential or combined administration modes with immune targeted therapy. Each cohort included 6-12 subjects at different dose levels, and three cohorts could be carried out at the same time.\n\nThe third stage is the dose expansion stage. According to the safety, PK and clinical data of the three cohorts in the second stage, 1-2 cohorts were selected by SMC for dose expansion. The sample size of each cohort was expanded to 20 cases on the original basis. The estimated ORR of the trial drug was 24%, and the ORR of the standard treatment was 5%. When the type I error was one-sided 0.025, and the power was 80%, the sample size was estimated by the normal approximation method. So each dose expansion phase A minimum of 20 subjects were required to be enrolled in the cohort.",[548],"Advanced Malignant Solid Tumor of Digestive System","2025-12-16",{"date":551,"type":32},"2025-12-23",{"date":553,"type":32},"2024-05-06",{"date":555,"type":21},"2027-10-30",{"name":38,"class":39},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":563,"maxAge":75,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":566,"briefSummary":567,"conditions":568,"keywords":573,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":582,"locationsCount":128},"100579987","effectiveness-of-digital-cognitive-behavioral-therapy-for-the-treatment-of-depression-a-real-world-study-100579987","NCT06831435","Effectiveness of Digital Cognitive Behavioral Therapy for the Treatment of Depression: a Real-world Study","Inclusion Criteria:\n\n1. Aged 14-60 years (including 14 and 60), no gender restriction;\n2. HAMD \\>= 14;\n3. Written informed consent obtained from the patient; written informed consent obtained from the guardian for minors.\n\nExclusion Criteria:\n\n* Persons with severe suicidal tendencies (item 10 of the MADRS scale ≥ 5).","14 Years",{"count":565,"type":21},325,[111],"The project proposes to develop a digital product based on cognitive behavioral therapy for the assisted treatment of depression. The digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. The therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including AI-guided course work and homework. This study aims to evaluate the therapeutic effects of CBT-based digital products for depression in patients through a real-world study, and to explore its genetic and neuroimaging mechanisms.",[569,570,571,572],"Depression","Bipolar Affective Disorder","Schizophenia Disorder","Psychiatric &Amp;or Mood Disorder",[574,575],"i-CBT","a real-world study","2025-12-08",{"date":578,"type":32},"2025-12-15",{"date":580,"type":32},"2024-11-13",{"date":454,"type":21},{"name":38,"class":39},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":591,"maxAge":18,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":594,"briefSummary":595,"conditions":596,"keywords":601,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":128},"100615545","shame-focused-cognitive-behavioral-therapy-for-reducing-suicide-risk-in-adolescent-psychiatric-inpatients-sf-cbt-100615545","NCT07294001","Shame-Focused Cognitive Behavioral Therapy For Reducing Suicide Risk In Adolescent Psychiatric Inpatients (SF-CBT)","A Pilot Randomized Controlled Trial Of Shame-Focused Cognitive Behavioral Therapy For Suicide Prevention In Adolescent Psychiatric Inpatients","SF-CBT","Inclusion Criteria:\n\n* Adolescents aged 13-18 years, male or female.\n* Recent suicide risk, defined as:\n\nAt least one suicide attempt in the past month, or Current suicidal ideation within the past month (with or without plan\u002Fintent) and at least one previous attempt.\n\n* Elevated shame level (baseline score ≥ 9 on the External and Internal Shame Scale, EISS).\n* Adequate cognitive capacity to participate in interviews and assessments.\n* Parent\u002Flegal guardian (or designated responsible adult authorized by guardian) provides informed consent and agrees to participate.\n\nExclusion Criteria:\n\n* Current manic episode.\n* History of schizophrenia spectrum disorder, intellectual disability, or organic brain disease.\n* Severe psychiatric or medical conditions that impair capacity for consent or participation.\n* Expected to receive electroconvulsive therapy (ECT) during hospitalization.\n* Anticipated inpatient stay shorter than 14 days (to ensure intervention completion).","13 Years",{"count":593,"type":21},42,[111],"This pilot randomized controlled trial (RCT) aims to evaluate the feasibility, acceptability, and preliminary efficacy of Shame-Focused Cognitive Behavioral Therapy (SF-CBT) among high-risk psychiatric inpatient adolescents. Shame has been identified as a critical psychological mechanism underlying suicidal ideation and behavior, yet few interventions directly target it. SF-CBT is a structured, manualized intervention designed to reduce shame, improve coping strategies, and lower suicide risk.\n\nApproximately 42 adolescents aged 13-18 years, admitted for recent suicide attempt or severe suicidal ideation, will be randomized in a 2:1 ratio to receive either SF-CBT or supportive therapy (ST). Both conditions include 7 individual sessions for adolescents and 3 structured psychoeducation sessions for parents\u002Fguardians.\n\nPrimary outcomes include feasibility metrics (recruitment, retention, adherence, fidelity, adverse events) and acceptability ratings from adolescents, parents, and therapists. Secondary outcomes include changes in suicidal ideation, suicidal behavior, shame, and coping styles, assessed at baseline, post-treatment, and 1-, 3-, and 6-month follow-ups.\n\nFindings will inform refinement of the intervention manual, establish feasibility benchmarks, and provide effect size estimates to guide a subsequent large-scale RCT.",[597,598,599,600],"Adolescent Suicide","Suicidal Ideation","Suicidal Behavior","Shame",[602,603,598,599,600,604,605,606,607,608,609],"Adolescents","Suicide Prevention","Cognitive Behavioral Therapy (CBT)","Shame-Focused Cognitive Behavioral Therapy (SF-CBT)","Randomized Controlled Trial (RCT)","Feasibility Study","Pilot Trial","Psychiatric Inpatient","2025-12-07",{"date":526,"type":32},{"date":613,"type":32},"2025-08-10",{"date":615,"type":21},"2026-09-30",{"name":38,"class":39},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":105,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":315,"phases":4,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":128},"100534092","peking-university-birth-cohort-in-weifang-pkubc-wf-100534092","NCT06234332","Peking University Birth Cohort in Weifang (PKUBC-WF)","Peking University Birth Cohort in Weifang","Inclusion Criteria:\n\n* Pregnant woman\n\n  1. Pregnant women, 6-13\\^+6 gestational weeks\n  2. Resided in Weifang in the past half years and have no plan to move out after delivery\n  3. Pregnant women who plan to have antenatal care and delivery in Weifang maternal\\&Child Hospital.\n  4. Pregnant women who is willing to participate in this study with informed consent\n* Pregnant woman's husband\n\n  1. His wife was eligible for enrollment\n  2. He is the biological father of the child (his wife's current pregnancy)\n  3. Pregnant women's husband who is willing to participate in this study with informed consent\n* Offspring 4. Children born to pregnant women who met the inclusion criteria after enrolling in this study.\n\n  5\\. Before the age of 8 years, his\u002Fher mother provided written informed consent. 6. After 8 years old, he\u002Fshe agreed to continue this study and signed the informed consent.\n\nExclusion Criteria:\n\n* Participants who cannot communicate normally.",{"count":625,"type":21},2800,"The PKUBC-WF is a prospective cohort study carried out in Weifang city of Shandong, China. The primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to before 18 years old. Biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces are also collected.",[628,629,630,631,632,378,633,634,635],"Health Problems in Pregnancy","Pregnancy Outcomes","Gestational Diabetes","Gestational Hypertension","Preterm Birth","Mother-Infant Interaction","Child Development","Anemia","2025-11-18",{"date":638,"type":32},"2025-11-24",{"date":640,"type":32},"2024-02-01",{"date":642,"type":21},"2043-12-31",{"name":38,"class":39},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":22,"phases":653,"briefSummary":654,"conditions":655,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":663,"locationsCount":4},"100609344","study-on-the-effect-of-online-cognitive-training-doses-on-cognitive-function-in-individuals-with-mild-cognitive-decline-100609344","NCT07213362","Study on the Effect of Online Cognitive Training Doses on Cognitive Function in Individuals With Mild Cognitive Decline","Study on the Effect of Different Doses of Computerized Cognitive Training on Cognitive Function in Patients With Mild Cognitive Impairment: An Open-Label, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 60 years.\n* Self-reported cognitive decline, confirmed by an informant.\n* Montreal Cognitive Assessment (MoCA) score of 19-25, adjusted for years of education (+1 point for 12 years or less).\n* Ability to complete activities of daily living independently.\n* Possesses basic communication skills and is able to cooperate with the study procedures.\n* Voluntarily agrees to participate in the study and signs the informed consent form.\n\nExclusion Criteria:\n\n* Presence of underlying neurological diseases that may impair cognitive function, including but not limited to dementia syndrome, Parkinson's disease, epilepsy, and cerebrovascular disease.\n* Presence of severe or unstable organic diseases such as cancer, hydrocephalus, history of central nervous system tumors, or acute brain injury\u002Finfection.\n* Diagnosis of severe mental illness such as major depressive disorder, schizophrenia, schizoaffective disorder, or bipolar disorder.\n* Presence of severe visual or hearing impairment, or other physical conditions that may interfere with the completion of the study.\n* Participation in any other clinical trial within the past 3 months.\n* Having received transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), light therapy, or having taken medications that could significantly affect cognitive function (e.g., nootropics, psychoactive drugs, anticholinergic drugs, benzodiazepines) for any reason within the past 6 months.\n* History of alcohol dependence or substance abuse.\n* Consumption of alcohol or other substances that affect cognitive function, such as caffeine or cocaine, within 24 hours prior to the cognitive assessment.\n\nAny other conditions that the investigator deems unsuitable for participation in this study.",{"count":652,"type":21},234,[111],"The primary questions that this clinical trial aims to answer are:\n\nTo compare the differences in the efficacy of different doses of Computerized Cognitive Training (CCT) in improving cognitive function among patients with Mild Cognitive Impairment (MCI), and to explore the potential optimal intervention dose.\n\nTo analyze the interaction between individual characteristics and the intervention dose of CCT.\n\nTo compare the improvement in functional activity ability of MCI patients among different CCT intervention dose groups.\n\nTo compare the symptoms of depression and anxiety among different CCT intervention dose groups.\n\nTo evaluate the adherence to different doses of CCT intervention.\n\nParticipants will:\n\nReceive CCT intervention at varying durations and frequencies over a 12-week period, and will be followed up for cognitive function, functional activity ability, etc., at weeks 4, 12, and 24.",[656],"Mild Cognitive Disorder","2025-10-01",{"date":659,"type":32},"2025-10-08",{"date":659,"type":21},{"date":662,"type":21},"2026-12",{"name":38,"class":39},""]